Genzyme Extends Deadline for Tender Offer to Acquire AnorMED Inc.
06 Oktober 2006 - 6:41PM
PR Newswire (US)
CAMBRIDGE, Mass., Oct. 6 /PRNewswire-FirstCall/ -- Genzyme
Corporation (NASDAQ:GENZ) announced today that it has extended its
offer to acquire the outstanding shares of AnorMED Inc.
(NASDAQ:ANOR) of Vancouver, British Columbia until 12:01 a.m.
Vancouver time on October 23, 2006. Prior to this extension,
Genzyme's offer was set to expire at 12:01 a.m. Vancouver time on
October 7. Genzyme offered on August 30 to acquire AnorMED's
outstanding shares for US $8.55 per outstanding share, or
approximately $380 million. Genzyme may elect to extend its offer
again by giving notice of such extension to AnorMED shareholders, a
copy of which will be filed with the securities regulatory
authorities in Canada and the United States and which should also
be made available by such authorities through the Internet at
http://www.sedar.com/ or http://www.sec.gov/. About Genzyme One of
the world's leading biotechnology companies, Genzyme is dedicated
to making a major positive impact on the lives of people with
serious diseases. This year marks the 25th anniversary of Genzyme's
founding. Since 1981, the company has grown from a small start-up
to a diversified enterprise with more than 8,500 employees in
locations spanning the globe and 2005 revenues of $2.7 billion.
Genzyme has been selected by FORTUNE as one of the "100 Best
Companies to Work for" in the United States. With many established
products and services helping patients in more than 80 countries,
Genzyme is a leader in the effort to develop and apply the most
advanced technologies in the life sciences. The company's products
and services are focused on rare inherited disorders, kidney
disease, orthopedics, cancer, transplant and immune diseases, and
diagnostic testing. Genzyme's commitment to innovation continues
today with a substantial development program focused on these
fields, as well as heart disease and other areas of unmet medical
need. Important Information Regarding the Tender Offer Investors
and security holders are urged to read the disclosure documents
filed with the Securities and Exchange Commission (the "SEC") from
time to time, including the tender offer statement filed on
September 1, 2006, regarding the tender offer by Genzyme's wholly
owned subsidiary, Dematal Corp., for all of the outstanding common
shares of AnorMED. Investors and security holders may obtain a free
copy of the disclosure documents and other documents filed by
Genzyme or Dematal with the SEC at the SEC's website at
http://www.sec.gov/. In addition, documents filed with the SEC by
Genzyme or Dematal may be obtained free of charge from Genzyme by
directing a request to Sally Curley at (617)768-6140. Genzyme(R) is
a registered trademark of Genzyme Corporation. All rights reserved.
Genzyme's press releases and other company information are
available at http://www.genzyme.com/ and by calling Genzyme's
investor information line at 1-800-905-4369 within the United
States or 1-703-797-1866 outside the United States. Media Contact:
Investor Contact: Dan Quinn Sally Curley (617) 768-6849 (617)
768-6140 DATASOURCE: Genzyme Corporation CONTACT: Dan Quinn
(Media), +1-617-768-6849, or Sally Curley (Investor),
+1-617-768-6140, both of Genzyme Corporation Web site:
http://www.genzyme.com/ Company News On-Call:
http://www.prnewswire.com/comp/113803.html
Copyright
Anormed Ord (MM) (NASDAQ:ANOR)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Anormed Ord (MM) (NASDAQ:ANOR)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Anormed Ord (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Anormed (MM) News-Artikel